Abstract
Bacterial respiratory infections are the main reason of morbidity and mortality among cystic fibrosis (CF) patients. In early childhood, the respiratory infections are due to Staphylococcus aureus and Haemophilus influenzae. In older CF patients, pathogenic Gram-negative bacteria like Achromobacter xylosoxidans, Burkholderia cepacia complex and especially Pseudomonas aeruginosa are more frequently seen. P. aeruginosa is a turning point in the respiratory disease in CF and its predominance increases with age. Bacteria use a variety of two-component systems (TCS) to differentially express virulence factors involved in both acute and chronic infections. Here, we review bacterial TCS as targets for antibacterial treatment for CF patients.
Keywords: Bacterial infections, cystic fibrosis, two-component systems, antibacterial treatment, respiratory infection, pathogen.
Current Drug Targets
Title:Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients
Volume: 18 Issue: 6
Author(s): Nadya Velikova*Jerry M. Wells
Affiliation:
- Host-microbe Interactomics Group, Department of Animal Sciences, Wageningen University, Wageningen,Netherlands
Keywords: Bacterial infections, cystic fibrosis, two-component systems, antibacterial treatment, respiratory infection, pathogen.
Abstract: Bacterial respiratory infections are the main reason of morbidity and mortality among cystic fibrosis (CF) patients. In early childhood, the respiratory infections are due to Staphylococcus aureus and Haemophilus influenzae. In older CF patients, pathogenic Gram-negative bacteria like Achromobacter xylosoxidans, Burkholderia cepacia complex and especially Pseudomonas aeruginosa are more frequently seen. P. aeruginosa is a turning point in the respiratory disease in CF and its predominance increases with age. Bacteria use a variety of two-component systems (TCS) to differentially express virulence factors involved in both acute and chronic infections. Here, we review bacterial TCS as targets for antibacterial treatment for CF patients.
Export Options
About this article
Cite this article as:
Velikova Nadya*, Wells M. Jerry, Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160208145934
DOI https://dx.doi.org/10.2174/1389450117666160208145934 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Never Sleep with Baby? Or Keep Me Close But Keep Me Safe: Eliminating Inappropriate “Safe Infant Sleep” Rhetoric in the United States
Current Pediatric Reviews Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied
Recent Patents on Anti-Cancer Drug Discovery A Novel Information Theoretic Approach to Gene Selection for Cancer Classification Using Microarray Data
Current Bioinformatics Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders
Current Pharmaceutical Design Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer Therapy
Current Cancer Drug Targets Mast Cells in Lung Homeostasis: Beyond Type I Hypersensitivity
Current Respiratory Medicine Reviews Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy
Reviews on Recent Clinical Trials Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets
Current Respiratory Medicine Reviews The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design Targeting Transcription Factors in Acute Leukemia in Children
Current Drug Targets Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Human Terminal Deoxynucleotidyl Transferases as Novel Targets for Anticancer Chemotherapy
Current Medicinal Chemistry